To those who say “impossible, impractical, unrealistic,” we say:
We are developing a new class of innovative medicines called
We’re committed to
ensuring broad patient
We are focused on diseases for which treatment options are limited or simply don't exist.
Updated as of March 2020
* 2 approved in the U.S. and European Union, 1 of which is approved in Brazil, Canada, Switzerland and Japan
Our robust pipeline contains therapies in late-stage (Phase 3) and early-stage (Phase 2 or earlier) trials. Our RNAi therapies leverage two distinct approaches to enable delivery of small interfering Ribonucleic Acid (siRNA): lipid nanoparticles (LNP) and GalNAc-conjugates.